QURE - uniQure N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

uniQure N.V.

Paasheuvelweg 25a
Amsterdam 1105 BP
Netherlands
31 20 240 6000
http://www.uniqure.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees212

Key Executives

NameTitlePayExercisedYear Born
Mr. Matthew Craig KapustaCEO, Interim CFO & Exec. Director883.62kN/A1972
Dr. Scott T. McMillanChief Operations Officer595.6kN/A1959
Ms. Maria E. CantorSr. VP of Investor Relations & Communication491.12kN/A1968
Mr. Jonathan GarenChief Bus. Officer560.13kN/A1966
Dr. Alexander E. Kuta Ph.D.Sr. VP of Regulatory Affairs594.99kN/A1960
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate Governance

uniQure N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.